Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890732 | 1.00 | KMT2A (0.38) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL26504466 | 0.98 | KMT2A (0.35) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL21579901 | 0.92 | MEN1 (0.37) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL24193595 | 0.89 | MEN1 (0.37) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL21099929 | 0.89 | KMT2A (0.39) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL26504470 | 0.88 | TSHR (0.39) | TSHRSMN1; SMN2HPGD | |
| SCHEMBL14453753 | 0.88 | CA12 (0.38) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL25746260 | 0.87 | MEN1 (0.42) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL25892281 | 0.87 | MEN1 (0.35) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL23157466 | 0.86 | CASP2 (0.43) | KMT2AMEN1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9138462-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9138462-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9133276-B2 | Prodrugs comprising an exendin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133276-B2 | Prodrugs comprising an exendin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | KMT2A 1601/4885MEN1 196/4885CA12 1487/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KMT2A 3136/4885MEN1 4821/4885CA12 2730/4885 |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | KMT2A 1601/4885MEN1 196/4885CA12 1487/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | KMT2A 3575/4885MEN1 118/4885CA12 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.